DOT1L

Across TCGA pan-cancer cohorts, DOT1L mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of DOT1L’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where DOT1L mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types DOT1L is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LSCC, CCRCC, and PDAC are the cancer types where DOT1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DOT1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	+0.421	<.001	7	view →
CCRCC	All	All	+0.438	.002	6	view →
PDAC	All	All	−0.783	.005	4	view →
LUAD	Male	All	+0.335	.002	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

DOT1L–LSCC

Open the LSCC breakdown →